Search Site

Trends banner

ADNOC Drilling H1 revenue $2.37bn

The company posted a net profit of $692m.

Eni profit falls due to dip in oil prices

Q2 net profit fell by 18% to $637 million.

Emirates NBD H1 profit $3.40bn

Total income rose by 12 percent in the same period.

ADIB H1 pre-tax profit $1.08bn

Q2 pre-tax net profit increases by 14 percent.

AstraZeneca to invest $50bn in US

Bulk of funds to go into a Virginia manufacturing center.

Jamjoom Tadawul debut on Jun 20

Jamjoom Pharma will debut on Tadawul on June 20. (Tadawul)
  • The company said the daily fluctuation limit is +/- 30% and static price fluctuation limit is +/-10%, Jamjoom said in a statement to Tadawul on Sunday.
  • The company offered 21 million shares, representing 30 percent of its share capital. The IPO was the largest in Saudi Arabia since Saudi Aramco Base Oil's IPO in Dec 2022.

Riyadh, Saudi Arabia — Jamjoom Pharmaceuticals Factory (Jamjoom Pharma) will start trading on the Saudi Exchange (Tadawul) on June 20, under the symbol 4015 and ISIN Code SA15QGU1UNH6.

The company said the daily fluctuation limit is +/- 30% and static price fluctuation limit is +/-10%, Jamjoom said in a statement to Tadawul on Sunday.

These fluctuation limits will apply during the first three days of listing, and from the fourth trading day onwards, the daily price fluctuation limits will revert to +/- 10% and the static price fluctuation limits will no longer apply.

Jamjoom Pharma’s IPO was launched on May 25, 2023 and it set the price at SAR 60 per share.
The company offered 21 million shares, representing 30 percent of its share capital.

The IPO was also the largest in Saudi Arabia since Saudi Aramco Base Oil Co.’s IPO in December 2022.

The retail offering was 11x covered, with a minimum of four shares allocated per retail subscriber. The remaining shares will be allocated on a pro-rata basis at 0.5146%, based on the demand size of every subscriber to total shares. Institutional subscription was 67.2x covered

The proceeds from the IPO will be used to fund Jamjoom Pharma’s growth plans, including expanding its manufacturing capacity, investing in research and development, and expanding its sales and marketing efforts.